3 different doses of Alethine that were logs apart (30 mg/kg, 30 ug/kg, and 600 ng/kg) either alone or in combination with low dose (10 ug per mouse for a total of 3 doses 3 days apart) anti-PD1 in the DBA mouse Cloudman melanoma mouse model were tested. The lowest dose of Alethine (600 ng/kg) in combination with anti-PD1 resulted in cures in 33% of the mice when treatment was initiated when tumors were of substantial size (average size of 30 mm2).

Alethine stimulated the HPBLS and murine splenocytes to produce immunoglobulinin a dose-dependent manner, with illustrated optimal concentrations of about 5-10 ng/ml culture. In HPBLS, comparatively little antibody production and nominal thymidine incorporation were observed with alethine at concentrations below 1 ng/ml (5-500 pg/ml).